Trazodone
| 證據等級: L5 | 預測適應症: 10 個 |
目錄
Trazodone: From Major Depressive Disorder to Obsessive-Compulsive Disorder
One-Sentence Summary
Trazodone is a triazolopyridine antidepressant internationally approved for Major Depressive Disorder; no SAHPRA-approved Professional Information is available because the product is not currently marketed in South Africa. The TxGNN model predicts it may be effective for Obsessive-Compulsive Disorder (OCD), with no registered clinical trials but 20 supporting publications, including one placebo-controlled RCT, currently available.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Major Depressive Disorder (based on general pharmacological knowledge; no local regulatory filing exists) |
| Predicted New Indication | Obsessive-Compulsive Disorder |
| TxGNN Prediction Score | 99.95% |
| Evidence Level | L3 |
| South Africa Market Status | Not Marketed |
| Number of SAHPRA Registrations | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Trazodone is a triazolopyridine-class antidepressant belonging to the SARI (Serotonin Antagonist and Reuptake Inhibitor) class. It modulates serotonergic transmission through 5-HT2A receptor antagonism combined with weak serotonin transporter (SERT) inhibition. A formal, DrugBank-verified mechanism-of-action record is currently a data gap; the description above is drawn from the supporting literature in this evidence pack.
Standard pharmacological treatment for OCD — clomipramine and the SSRIs — also targets the serotonin system, so there is a plausible mechanistic link between trazodone’s pharmacology and OCD. Depression and OCD frequently co-occur, and several of the case reports below describe patients whose OCD improved alongside comorbid depressive symptoms while on trazodone. A 2015 review (PMID 26088119) further notes that off-label trazodone use already extends to OCD, generalized anxiety disorder, panic disorder, and PTSD in clinical practice.
However, trazodone’s serotonin-reuptake-inhibiting effect is considerably weaker than that of the SSRIs that are the evidence-based standard of care for OCD, so its clinical efficacy in this indication remains uncertain and should be regarded as adjunctive or reserved for treatment-resistant cases rather than as a primary therapy.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 1629380 | 1992 | RCT | Journal of Clinical Psychopharmacology | Double-blind, placebo-controlled trial of trazodone in OCD patients, investigating its serotonin-reuptake-inhibiting properties as a potential anti-obsessional treatment |
| 8993077 | 1996 | Review | Psychopharmacology Bulletin | Discusses mono- and polypharmacotherapy of OCD; notes OCD responds specifically to serotonin reuptake inhibitors |
| 8134850 | 1994 | Review | Southern Medical Journal | Reviews pharmacologic management of OCD and the serotonin/dopamine dysregulation hypothesis |
| 8331098 | 1993 | Review | The Journal of Clinical Psychiatry | Reviews biological approaches for treatment-resistant OCD, focused on augmentation of serotonergic therapy |
| 27744763 | 2017 | Review | Postgraduate Medicine | Comprehensive review of trazodone’s MOA, formulations, and use across psychiatric and medical conditions, including non-FDA-approved indications |
| 26088119 | 2015 | Review | Current Pharmaceutical Design | Reviews off-label trazodone prescribing, including evidence, benefits, and risks in OCD and other anxiety-spectrum conditions |
| 2119885 | 1990 | Case Series | Clinical Neuropharmacology | Trazodone given to 9 clomipramine-resistant OCD patients; mild overall improvement, 3 patients responded favorably |
| 3501130 | 1987 | Case Series | Psychopathology | PET study correlating trazodone treatment response in OCD with changes in caudate nucleus glucose metabolism |
| 4009160 | 1985 | Case Report | The Journal of Nervous and Mental Disease | Two treatment-refractory OCD-with-depression patients showed rapid improvement in both conditions on trazodone |
| 8434675 | 1993 | Case Report | The American Journal of Psychiatry | Case report of trazodone treatment for comorbid OCD and trichotillomania |
South Africa Market Information
Trazodone is currently not registered with SAHPRA (0 licenses on file), and no locally approved Professional Information exists for this product.
Safety Considerations
Please refer to the SAHPRA-approved Professional Information (PI) for safety information. Report adverse drug reactions to SAHPRA.
Conclusion and Next Steps
Decision: Hold
Rationale: Evidence is limited to one small placebo-controlled RCT plus a handful of older case reports/series (Evidence Level L3), with no ongoing clinical trials and no local SAHPRA registration or safety documentation — including a Blocking data gap on TFDA/SAHPRA-approved warnings and contraindications.
To proceed, the following is needed:
- SAHPRA-approved Professional Information (warnings, contraindications, DDI) — currently a Blocking data gap
- Verified mechanism-of-action data from DrugBank
- A modern, adequately powered RCT confirming efficacy specifically in OCD (vs. established SSRIs/clomipramine)
- Confirmation of local market entry pathway, since trazodone is not currently registered in South Africa
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.